Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

Feature | November 25, 2013
November 25, 2013 – Combining genetic data with clinical information to determine the initial dosage of the blood...
antiplatelet therapy clinical trial blood test platelet function corgenix
News | November 15, 2013
November 15, 2013 — A study conducted in Ireland found that aspirin does not adequately protect 20 percent of patients...
Feature | November 14, 2013
November 14, 2013 — Professional cardiovascular societies and many working cardiologists question the U.S. Food and...
Blog | November 08, 2013
By Dave Fornell, DAIC editor The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT)...
News | November 04, 2013
November 4, 2013 — A new study demonstrated that some patients may not need to receive prolonged anti-clotting therapy...
cath lab clinical trial study pharmaceuticals antiplatelet therapy arctic
Feature | November 04, 2013
November 4, 2013 — Patients who do not experience a major cardiac event in the first year after receiving drug-eluting...
cath lab cardiac diagnostics genetic testing antiplatelet therapy blood monitors
Feature | November 04, 2013
November 4, 2013 — According to a new study, genetic profiling of patients undergoing percutaneous coronary...
Feature | November 01, 2013
November 1, 2013 — According to a new study, administering the blood thinner bivalirudin to patients experiencing an ST...
xience prime xpedition V antiplatelet stents eluting clinical trial study cath
News | October 31, 2013
October 31, 2013 — Abbott announced it plans to initiate a randomized, controlled trial in the United States to...
News | October 24, 2013
October 24, 2013 – PDI, Inc. and Transgenomic, Inc. announced the signing of a U.S. collaboration agreement to...
Icahn School of Medicine at Mount Sinai PARIS Study Antiplatelet Therapy PCI
Feature | September 26, 2013
September 26, 2013 — Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of...
News | September 23, 2013
September 23, 2013 – Aggredyne Inc., has received ISO 13485 certification for its quality control program related to...
News | September 18, 2013
September 18, 2013 — Decision Resources forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among...
Technology | September 13, 2013
September 13, 2013 — Atherotech Diagnostics Lab has added three new genetic tests to its cardiometabolic test offering...
Feature | September 05, 2013
September 5, 2013 — Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with...